Communiqués Artelo Biosciences, Inc.

Actions

ARTL

US04301G8050

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
3,410 ^USD	-1,45%		-15,59%	-89,65%

23/09	Artelo Biosciences, Inc. dépose une nouvelle demande de brevet provisoire couvrant Art27.13 contre l’obésité, seul et en association avec des agonistes des récepteurs du GLP-1	CI
16/09	Artelo Biosciences, Inc. annonce que l'ART27.13 permet une perte de poids comparable au sémaglutide et double la perte de poids en association dans un modèle d'obésité non clinique	CI

Communiqués

07/10	Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform	AQ
23/09	Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings	AQ
16/09	Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity	AQ
08/09	Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
27/08	Artelo Biosciences Announces Reverse Stock Split	AQ
20/08	Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13	AQ
17/08	Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies	AQ
13/08	Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results	AQ
10/08	Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma	AQ
23/07	New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition	AQ
22/07	New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition	AQ
16/07	Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions	AQ
14/07	Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026	AQ
13/07	Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy	AQ
01/07	Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury	AQ
30/06	Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026	AQ
29/06	Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026	AQ
10/06	Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success	AQ
14/05	Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results	AQ
28/04	Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development	AQ
20/04	Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile	AQ
07/04	Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements	AQ
27/03	Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	AQ
25/03	Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments	AQ
25/03	Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength	AQ